Stephen Elliman

Orbsen Therapeutics Ltd. operates as a regenerative medicine company. It engages in the development of therapies including Acute Respiratory Distress Syndrome, Diabetic Foot Ulcers, Diabetic Kidney Disease, Primary Sclerosing Cholangitis, and Sepsis. The company was founded in 2006 and is headquartered in Galway, Ireland.

Orbsen Therapeutics Ltd. operates as a regenerative medicine company. It engages in the development of therapies including Acute Respiratory Distress Syndrome, Diabetic Foot Ulcers, Diabetic Kidney Disease, Primary Sclerosing Cholangitis, and Sepsis. The company was founded in 2006 and is headquartered in Galway, Ireland.

Orbsen Therapeutics Ltd. operates as a regenerative medicine company. It engages in the development of therapies including Acute Respiratory Distress Syndrome, Diabetic Foot Ulcers, Diabetic Kidney Disease, Primary Sclerosing Cholangitis, and Sepsis. The company was founded in 2006 and is headquartered in Galway, Ireland.

Orbsen Therapeutics Ltd. operates as a regenerative medicine company. It engages in the development of therapies including Acute Respiratory Distress Syndrome, Diabetic Foot Ulcers, Diabetic Kidney Disease, Primary Sclerosing Cholangitis, and Sepsis. The company was founded in 2006 and is headquartered in Galway, Ireland.

Orbsen Therapeutics Ltd. operates as a regenerative medicine company. It engages in the development of therapies including Acute Respiratory Distress Syndrome, Diabetic Foot Ulcers, Diabetic Kidney Disease, Primary Sclerosing Cholangitis, and Sepsis. The company was founded in 2006 and is headquartered in Galway, Ireland.